Destiny Pharma (DEST) Insider Trading & Ownership GBX 3 -1.29 (-30.05%) (As of 08/12/2024) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartHeadlinesInsider Trades Destiny Pharma (LON:DEST) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage25.94%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)£3,100.00Number OfInsiders Selling(Last 12 Months)0 Get DEST Insider Trade Alerts Want to know when executives and insiders are buying or selling Destiny Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address DEST Insider Buying and Selling by Quarter Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Destiny Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/2/2024Nigel RuddInsiderBuy1,240,000GBX 0.25£3,100 (Data available from 1/1/2013 forward) DEST Insider Trading Activity - Frequently Asked Questions Who is on Destiny Pharma's Insider Roster? The list of insiders at Destiny Pharma includes Nick Rodgers, and Nigel Rudd. Learn more on insiders at DEST. What percentage of Destiny Pharma stock is owned by insiders? 25.94% of Destiny Pharma stock is owned by insiders. Learn more on DEST's insider holdings. Which Destiny Pharma insiders have been buying company stock? The following insiders have purchased DEST shares in the last 24 months: Nick Rodgers (£22,137.87), and Nigel Rudd (£3,100). How much insider buying is happening at Destiny Pharma? Insiders have purchased a total of 1,309,477 DEST shares in the last 24 months for a total of £25,237.87 bought. Destiny Pharma Key ExecutivesDr. William Guy Love (Age 62)Founder, Chief Scientific Officer & Director Compensation: $265kMr. Shaun Claydon ACA (Age 56)CFO, Company Secretary & Director Compensation: $286kDr. Debra Barker M.D. (Age 62)MSc., Interim CMO & Senior Independent Director Compensation: $41kMr. Christopher John Tovey BSc (Age 59)CEO & Director More Insider Trading Tools from MarketBeat Related Companies ONC Insider Trading BVX Insider Trading ROQ Insider Trading FAB Insider Trading OBD Insider Trading RENE Insider Trading OCTP Insider Trading ONT Insider Trading GNS Insider Trading OXB Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (LON:DEST) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Destiny Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Destiny Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
